Since a loss of PTEN decreases homologous recombination and sensitizes tumor cells to polyadenosine diphosphate ribose polymerase (PARP) inhibitors, a combination of PARP-inhibitor with PIK3-inhibitor could be promising for cancers with PTEN loss of function mutations [84]. The gene discussed is PIK3CG; the disease is neoplasm.